Introduction
Aspergillosis in captive and free-ranging birds remains one of the most frequently encountered and diffi cult-to-treat diseases in avian medicine. Waterfowl are particularly susceptible to this fungal disease, and when debilitated birds are intensively managed for rehabilitation, acute aspergillosis frequently develops and its prevention and treatment is important for a successful outcome [1] . Aspergillus fumigatus treating aspergillosis in birds, but it has limited bioavailability due to low solubility and possibly fi rst-pass metabolism in the intestine [5, 6] .
More recently, voriconazole (VRC; Vfend ™ , Pfi zer Pharmaceuticals, New York, NY), a second generation triazole, has been commercially developed for treating mycotic infections in humans [7, 8] . VRC is a synthetic derivative of fl uconazole and can be administered by intravenous or oral routes. In humans, VRC exhibits excellent oral bioavailability, wide tissue distribution, including the central nervous system, and has broad spectrum antifungal activity. When given prophylactically to lung transplant human patients, VRC was found in higher concentrations in the pulmonary epithelial lining fl uid as compared to plasma [9] . In vitro , VRC is fungicidal for numerous fungi and appears to have advantages over itraconazole [10 -12] . VRC has in vivo effi cacy against experimentally-induced systemic and pulmonary aspergillosis in mammals [13 -17] , and is now the recommended therapy for treating invasive and anti-fungal resistant aspergillosis in humans [18] [19] [20] [21] [22] .
The pharmacokinetics of VRC have been evaluated for numerous rodents [23, 24] , as well as horses [25, 26] , and humans [8] , and several bird species including African grey parrots [27] , Hispaniolan Amazon parrots [28] and domestic pigeons [29] . VRC exhibits non-linear pharmacokinetics with capacity-limited clearance and autoinduction of VRC metabolism by cytochrome P450 enzymes after multiple dosing in mice, rats, and dogs but not in other mammals [23] ; non-linear pharmacokinetics have also been observed in birds [27, 29] .
Methods for quantifying VRC include high and ultra performance liquid chromatography (HPLC and UPLC, respectively) and bioassay. HPLC and UPLC methods can be used for quantitative assays of specifi c compounds, whereas a bioassay offers information regarding the total biological activity of the antifungal agent and any metabolites. UPLC, a variation of HPLC, uses smaller particle size columns resulting in better separation and faster sample analysis. In human medicine, HPLC and bioassay have proven to be comparable in their measurements of VRC, and biologically active metabolites have not been identifi ed [30, 31] . Thus far, no biologically active metabolites of VRC have been identifi ed in animal models. To date, no such comparative laboratory methods have been performed on samples from birds. The advantages of the bioassay are a decreased need for highly specialized and costly analytical equipment, and relatively easy training of personnel to perform the tests. In addition, the bioassay potentially could be used in a specialized rehabilitation facility allowing the clinical monitoring of VRC concentrations on a regular basis.
The objectives of this study were to characterize the pharmacokinetics of VRC in adult mallard ducks and to determine if there was a difference between administration of the drug with or without a liquid diet. In addition, analytical assay methods were compared.
Materials and methods
To characterize the pharmacokinetics of VRC in adult mallard ducks ( Anas platyrhynchos ), as a model waterfowl species, this study was divided into three phases. Initially, three dosages of VRC were administered orally to mallard ducks to determine a dose likely to achieve blood concentrations at or above the concentration needed to inhibit A. fumigatus . The data from the dose range fi nding study was also used as a pilot assessment of the potential for dose linearity. Next, intravenous (IV) and oral (PO) administration routes were compared in a single dose study to determine bioavailability. For the bioavailability portion of the study, plasma VRC concentrations were measured using UPLC and compared to total antifungal activity as measured by bioassay to establish if both methods are reliable means for measuring VRC in plasma samples from ducks. In the last study phase, VRC was administered with and without liquid diet once daily for 21 days at a 20 mg/kg dose. For all three study phases, in addition to plasma samples, tissues of interest were collected for histology and VRC analysis.
Animals
Thirty-two (15 females, 17 males) adult domestic mallard ducks (average weight 1.06 Ϯ 0.11 kg SD) were used in the three study phases; (1) dose range fi nding and dose linearity pilot study ( n ϭ 7), (2) bioavailability study ( n ϭ 6), and (3) multiple dosing regimen of VRC administered with liquid diet ( n ϭ 6) vs. without liquid diet ( n ϭ 12) birds. One control bird (for histology) was held for 21 days then euthanized. All ducks were determined healthy by physical examination. During the studies the ducks were observed on a daily basis to evaluate activity, ambulation, food consumption, fecal output, and visual disturbances. In addition, physical examinations were performed and body weights were obtained on a weekly basis. The ducks were housed in temperature-controlled, lighted rooms with access to pools for swimming. A commercial waterfowl diet (Purina Game Bird Chow, Purina Mills LLC, St. Louis, MO USA) was provided ad libitum , except for periods 1 h before through 1 h after VRC administration. The study procedures were approved by the Institutional Animal Care and Use Committee of the University of California at Davis.
Drug administration and sample collection
Phase I. Dose range fi nding and dose linearity pilot study . A dose-range fi nding study was conducted to determine a 1, 2, 4, 8, 12, 24 , and 36 h post-administration; plasma was collected and stored in the same manner as previously described. After a 19-day wash-out period, the treatment groups were reversed. Ducks administered VRC IV in the fi rst period received VRC PO in the second period and vice versa. After the 36 h blood samples were taken in the second period, ducks were euthanized for collection of lung, liver, and kidney tissues as previously described. The right kidney was harvested since the intravenous drug administration was via the right metatarsal vein.
Phase III: Multiple dose pharmacokinetic study . A multiple dose study evaluating VRC administered with liquid diet (VRC-liquid diet; n ϭ 6) and without liquid diet (VRC-w/o liquid diet; n ϭ 12) was conducted. The liquid diet was the same one used for Phase 1 of the study. VRC was administered PO once daily (20 mg/kg) for 21 days. The data from the initial dose-range fi nding study indicated a short elimination half-life; however, a once daily treatment regime was selected as this would be the most common dosing interval used in rehabilitation facilities due to the need to minimize patient handling. Birds were observed on a daily basis (ambulation, alertness, consistency of fecal output, food and water consumption); every 7 days physical examinations were performed and body weights obtained. For birds in both VRC-liquid diet and VRC-w/o liquid diet groups, food and water were removed 1 h before drug administration. VRC treatment was administered concurrently with a liquid diet (VRC-liquid diet) or the drug was administered without simultaneous administration of liquid food (VRC-w/o liquid diet).
For the VRC-w/o liquid diet group of birds ( n ϭ 12), blood samples were taken just before VRC administration and at 0.5, 1, 2, 4, 8, 12 , and 24 h post-administration on days 1, 7, 14, and 21 of treatment; plasma was collected and stored in the same manner as previously described. Two birds were euthanized for tissue collection 24 h after VRC administration on days 1, 7, and 14, and the remaining 6 treated birds were euthanized on day 21. UPLC analysis of plasma samples for VRC concentrations were limited to the 6 birds that were treated for 21 days.
For the VRC-liquid diet birds ( n ϭ 6), ducks were administered VRC daily PO for 21 days. Solid food and water were removed 1 h prior to dosing, but 15 ml liquid diet was administered via gavage just before delivery of the VRC oral suspension. To assess the relative bioavailability of the drug when administered simultaneously with liquid diet, on day 1 of the study, blood samples were taken at times identical to the bioavailability study (0.123, 0.25, 0.5, 0.75, 1, 2, 4, 8, 12 , and 24 h post-VRC administration). Samples were also taken on days 7, 14, and 21, blood was sampled just before the day ' s dose was administered and dose that came closest to maintaining plasma concentrations above a targeted MIC of 0.5 μ g /ml and not exceeding maximal trough concentrations (trough C max ) of 5.5 μ g/ ml. An MIC of VRC of 0.5 μ g/ml was selected based on an avian study that reported an MIC 90 for 59 avian A. fumigatus isolates as 0.5 μ g/ml [29] . Trough plasma concentrations associated with treatment success in humans range from a minimum of 1 μ g/ml to a maximum of 5.5 μ g/ml [31] . The dose range fi nding data was also used for preliminary assessment of dose linearity. Oral (PO) doses were administered at 10 mg/kg ( n ϭ 2), 20 mg/kg ( n ϭ 2), and 40 mg/kg ( n ϭ 3). Food and water were removed 1 h before VRC administration then replaced 1 h after administration. In attempts to simulate nutritional support that a typical sick anseriform patient would receive, ducks were gavage-fed 15 ml of liquid diet (Emeraid II, Lafeber, Cornell, IL, USA) immediately before administering the VRC suspension (40 mg/ml; Vfend, Pfi zer Inc, New York, NY, USA). Blood samples (0.5 -1.0 ml) were collected just prior to VRC administration and at 0.5, 1, 2, 4, 8, 12, and 24 h post-administration. The total blood volume sampled from each animal was approximately 1% of the bird ' s body weight. Blood samples were transferred immediately into heparinized tubes, placed on ice and centrifuged at 3000 g for 10 min. The plasma was collected and the resulting samples were stored at Ϫ 80 ° C until analysis. After the 24 h blood samples were taken, the ducks were euthanized and liver, lung, and kidney samples were collected from each animal and placed in either 10% formalin for histopathologic evaluation or frozen at Ϫ 80 ° C until analyzed for VRC concentrations.
Phase II: Bioavailability . A bioavailability study was conducted comparing PO and IV routes of administration in a two-period crossover design. During the fi rst period, three ducks either received an IV or PO VRC treatment. Given that VRC administration with food has been reported to reduce bioavailability in humans [32] , the ducks were administered 10 mg/kg VRC oral suspension without liquid diet in order to determine the greatest potential bioavailability. For the IV treatment, the VRC solution (Vfend IV, Pfi zer Inc, New York, NY, USA) was diluted to 5 mg/ ml with 0.9% (w/v) sterile saline and administered at a dosage of 10 mg of VRC per kg of body weight gradually over 1 min via a 25 ga. 3/4 inch butterfl y catheter placed in the right medial metatarsal vein. Although there was the potential for a renal-portal system fi rst pass effect, this vessel was chosen since it was the best site for stabilizing the butterfl y catheter with manual restraint and a bandage could be secured to the leg post drug administration to minimize drug leakage. Blood samples were taken just before VRC administration and at 0. 123, 0.25, 0.5, 0.75, at 0.5, 1, 2, 4, 8, 12 , and 24 h post-administration. Plasma was collected and stored in the same manner described previously. All six ducks were euthanized 24 h after the last dose was administered on day 21. At the time of euthanasia, the 24 h blood sample was taken and tissue samples were harvested and stored as previously described.
Sample analysis
Ultra or High Performance Liquid Chromatography (plasma and tissue samples, respectively) . For all three study phases, plasma samples were analyzed using UPLC. Plasma samples (250 μ l) were prepared on cyanopropyl solid phase extraction cartridges (Bond-Elut CN-E, 50 mg, 1 ml, Varian Inc, Palo Alto, CA, USA) according to the procedure described previously [26] . Methanol extracts were dried under nitrogen at 40 ° C, reconstituted in 250 μ l mobile phase, and centrifuged at 14,000 g for 5 min at 20 ° C before analysis on an UPLC system (Aquity UPLC with TUV Detector, Waters Corporation, Milford, MA, USA). The isocratic mobile phase was 37:63 (vol:vol) acetonitrile-water with 0.02% trifl uoroacetic acid and the fl ow rate was 0.25 ml/min. Injection volume was 5 μ l and VRC was separated by a BEH C18 column, 1.7 μ m, 2.1 ϫ 50 mm (Waters Corporation, Milford, MA, USA) and detected by UV absorption at 263 nm. Calibration standards of VRC were prepared in mobile phase, ranging from 0.02 -5.0 μ g/ml (R 2 ϭ 0.997) and quality control plasma samples, fortifi ed at 0.05, 0.2, and 1.0 μ g/ml of VRC by spiking with methanolic standard solutions, were run daily. VRC recovery in the quality control plasma samples analyzed by UPLC was 78.6%. All plasma data were adjusted to refl ect recovery. The assay ' s limit of detection and quantifi cation were 0.005 μ g/ml and 0.02 μ g/ml, respectively. Intra-and inter-assay coeffi cients of variation were 12% and 24%, respectively.
High performance liquid chromatography (HPLC) was used for analyzing the tissue samples. Samples of liver, lung and kidney from all study phases were weighed in 250 Ϯ 10 mg portions and homogenized in 1.5 ml acetonitrile. The homogenate was centrifuged at 14,000 g for 10 min, the acetonitrile extract collected, and the pellet suspended in another 1.5 ml acetonitrile. The centrifugation was repeated and the second acetonitrile extract was added to the fi rst. Hexane, 1.0 ml, was added to the combined acetonitrile extract and gently mixed by shaking before centrifugation at 1,750 g for 10 min. The hexane layer was discarded and the acetonitrile extract dried under nitrogen at 40 ° C. Dried extract was suspended in 250 μ l acetonitrilewater (37:63) with 0.02% trifl uoroacetic acid and centrifuged at 14,000 g for 10 min before HPLC analysis (Alliance ® 2695 with 2996 PDA Detector, Waters Corporation, Milford, MA, USA). A mobile phase gradient was used with 0.02% trifl uoroacetic acid in water (mobile phase A) and 0.02% trifl uoroacetic acid in acetonitrile (mobile phase B). The gradient started with 100% A from 0 -3 min, switched to 50% A/50% B from 3 -13 min and held from 13 -18 min, then rapidly switched to 100% B at 18.1 min and held until 23 min before recovering to 100% A at 23.1 min and holding to 30 min before the next injection. Flow rate was constant at 1.0 ml/min, injection volume was 25 μ l and a Zorbax RX-C8 column, 5 μ m, 4.6 ϫ 250 mm (Agilent Technologies, Wilmington, DE, USA) was used and detection was by UV absorption at 263 nm. Calibration standards were 0.2 -10 μ g/g for tissue analysis (R 2 ϭ 0.985) and quality control samples of fortifi ed tissues were 0.5, 1.0, and 5.0 μ g/g. The assay limit of detection and quantifi cation were 0.1 μ g/g and 0.2 μ g/g, respectively. Average recoveries of VRC from quality control tissue samples were 83.7% in liver, 79.2% in lung, and 77.1% in kidney. Tissue concentrations were adjusted to refl ect these recoveries. Intra and inter-assay coeffi cients, respectively, were as follows: 9.6% and 10.8% for liver; 4.4% and 17.7% for lung; 7.1% and 13.1% for kidney.
Bioassay (plasma samples)
. To compare the UPLC assay to an alternative laboratory testing method and account for any possible additional antifungal activity from VRC metabolites, plasma samples from the bioavailability phase of the study were also analyzed by a previously described bioassay [13, 33] . In brief, Candida kefyr was maintained on Sabouraud ' s dextrose agar slants. Prior to use, the organism was inoculated into Synthetic Amino Acid Medium for Fungi (SAAMF) broth [34] . The culture was incubated overnight on a gyratory shaker (140 rpm) at 35 ° C in ambient air. Agar for the bioassay was prepared by mixing equal volumes of sterile, molten 3% Bacto-agar (at 50 ° C) and 2X SAAMF broth. C. kefyr was added to a fi nal concentration of 2.2 ϫ 10 5 yeast cells per ml and 150 ml poured into sterile, level, square plastic bioassay plates (245 by 245 mm). The agar was allowed to solidify at room temperature for 45 min, and 5-mm-diameter wells (36 per plate) were cut, using a sterile cork borer. Wells were loaded with 22 μ l of sample. Plasma samples from treated birds were analyzed in duplicate. Standards were placed on each plate in duplicate at two-fold concentrations from 4 -0.063 μ g/ml of VRC made in bird plasma. The lower limit of detection for the bioassay is 0.063 μ g/ml of VRC. Plates were incubated at 4 ° C for 1 h and then at 35 ° C for 12 -14 h. Zone diameters were measured to the nearest 0.1 mm, using a vernier caliper. Each well was measured in two directions, and the average of the two measurements was taken as the zone diameter for that well. Zone areas were computed as the area of the clear zone minus the area of the sample well. A standard curve was constructed by plotting zone area versus log 10 VRC concentration. VRC concentrations in bird plasma samples were interpolated from the standard curve constructed from the same plate.
Data analysis
Pharmacokinetic analysis . Data analysis included evaluation of time versus concentration data using a commercial pharmacokinetic analysis software program (WinNONLIN version 5.1; Pharsight Corp., Mountain View, CA, USA). Plasma VRC concentration-time data were analyzed using both compartmental modeling and noncompartmental analysis. The goodness of fi t for the data with the predicted model was based upon Akaike ' s information criterion [35] and visual inspection of the residuals.
A one-compartment open model with fi rst-order absorption and fi rst-order elimination was used. The primary parameters calculated included volume of the central compartment (V c ), and the rate constants of absorption (K abs ) and elimination (K el ). Secondary parameters calculated included the half-lives of absorption (T 1/2abs ) and elimination (T 1/2el ), the maximum calculated plasma concentration (C max ) and the time at which it occurred (T max ). The area under the curve from time zero extrapolated to infi nity (AUC 0 → ∞ ) was calculated using the trapezoidal method. To compare overall drug exposure between birds given multi ple doses of VRC with and without liquid diet, the trapezoidal method was used to calculate the AUC t , which repre sents the AUC from time 0 to the last time point at which VRC concentration was measurable for individual birds.
Statistical analysis . VRC concentrations as measured by UPLC and bioassay were compared using the Bland and Altman graphical approach [36] using a commercial software program (Analyse-it Standard Edition, Analyse-it Software, Ltd., Leeds, United Kingdom). In the multiple dose studies, noncompartmental parameters were compared between fed and fasted groups and analyzed for changes over time using a mixed effects linear model with a repeated measures design. Analyses were done in R [37] using the package ' NLME ' [38] . Descriptive statistics were calculated for tissue samples at each sampling point for each treatment group.
Results

Phase I. Dose range fi nding study and dose linearity
No signs of VRC toxicity (visual disturbances, diarrhea, vomiting, neurological abnormalities) were seen at any of the dosages. Plasma VRC concentrations for all three doses evaluated are reported in Table 1 . The 20 mg/kg dose was closest to maintaining plasma concentrations at 0.5 μ g/ml without exceeding a trough C max of 5.5 μ g/ml during a dosing interval that would be practical for an anseriform patient (at least 8 h or more). Plasma VRC concentrations were above 0.5 μ g /ml for a minimum of 5.2 h (10 mg/kg PO) and a maximum of 12 h (40 mg/kg; Table 2 ). Incremental doubling of the VRC dosage increased the C max and AUC 0 → ∞ (Table 2) . These increases were not proportional.
Phase II. Bioavailability
Signs of toxicity were not observed when birds were administered VRC IV or PO at 10 mg/kg body weight. Plasma VRC concentrations (as measured by UPLC or bioassay) are presented in Fig. 1A & B. A Bland-Altman percent difference plot comparing VRC concentrations determined using UPLC and bioassay methods is shown in Fig. 2 . From this plot an overall positive bias ( ϩ 23.5%) can be seen in the results produced by the bioassay (t 84 ϭ 5.97, P Ͻ 0.001) compared to the UPLC (i.e., the bioassay VRC concentrations tended to be higher than the UPLC values for the same sample). A linear regression indicated no signifi cant relationship between the percent differences between methods and the mean values (F 1,83 ϭ 2.94, P ϭ 0.09; F 1,83 ϭ 1.33, P ϭ 0.25 with one outlier removed).
Compartmental and non-compartmental pharmacokinetic parameters based on UPLC determined plasma VRC concentrations after IV and PO administration are presented in Table 3 . The IV data best fi t a one compartment open model with fi rst-order elimination and the PO data best fi t a one compartment open model with fi rst-order absorption and elimination, both weighted by the inverse square of the predicted concentration. Though the groups Table 1 Plasma voriconazole concentrations ( μ g/ml; corrected for 78.7% recovery), as determined by ultra performance liquid chromatography, for mallard ducks ( n ϭ 7) after single 10, 20 or 40 mg/kg oral doses of voriconazole. Liquid diet (15 ml) was administered simultaneously with the drug. crossed over only comprised three ducks each, there appeared to be a potential sequence effect in the area under the concentration-time curve (projected to infi nity, AUC 0 → ∞ ). AUC 0 → ∞ (calculated from UPLC data) after PO administration was lower in the ducks that were administered the IV dose fi rst (6.55, 7.62, and 7.74 μ g • h/ml) than in na ï ve ducks (10.19, 11.10, and 11.22 μ g • h/ml). Terminal elimination rate constants ( λ z ) did not differ signifi cantly between IV and PO pharmacokinetic profi les (paired t-test, P ϭ 0.61).
Concentration of VRC (
Phase III. Multiple dose pharmacokinetic study of fed vs. fasted birds
Signs of toxicity were not observed when VRC was administered with or without liquid diet at 20 mg/kg SID for 21 days. Compartmental and non-compartmental pharmacokinetic parameters are presented in Tables 4 and 5, respectively. There was no statistically signifi cant effect on the overall average of any of the pharmacokinetic parameters for VRC-liquid diet vs. VRC-w/o liquid diet ducks, with the exception of T max and AUC t . These differences were not considered clinically relevant. All parameters except T max varied signifi cantly over the 21-day course of the study (i.e., the ' time ' factor in the linear mixed model was signifi cant). Several parameters, including AUC t, C max, and T C Ͼ 1 decreased from day 1 to day 14, then increased again on day 21, when averaged over both VRC-liquid diet and VRC-w/o liquid diet groups. When taken separately, the VRC-w/o liquid diet group retained this pattern of decrease followed by an increase, while in the VRC-liquid diet group AUC t, T C Ͼ 0.5, and T C Ͼ 1 continued to decrease throughout the study. Averaged over both groups λ z increased after day 1 and remained elevated; λ z increased after day 1 in the VRC-liquid diet group but decreased slightly over time in the VRC-w/o liquid diet group. T 1/2 λ z averaged over all ducks decreased after day 1 and remained low. In the VRC-liquid diet group T 1/2 λ z decreased over the study period, while in the VRC-w/o liquid diet group T 1/2 λ z was elevated on day 21. VRC tissue concentrations (as measured by HPLC and adjusted for recovery) for all three study phases are summarized in Table 6 . The VRC concentrations for most of the liver, kidney, and lung samples taken 24 or 36 h after dosing were below the lowest calibration standards ( Ͻ 0.1 μ g/g). Thus, meaningful quantitative comparisons could not be made. Birds dosed at 20 mg/kg (versus10 mg/kg) had more VRC tissue concentrations that were measurable. There did not appear to be any increase in tissue concentrations as treatment time lengthened.
Histology (Study Phases I -III)
All birds, including the single control bird, had mild to moderate portal infl ammation (Table 7) . Most birds had mixed infl ammatory cells in the portal regions comprised of heterophils, macrophages and lymphocytes, and in two birds, portal infi ltrates were primarily lymphocytes. Roughly, half of the birds had grey/brown pigment within Kupffer cells at all time points. Rare small foci of necrosis were seen in two birds, one that was sacrifi ced one day post-treatment (VRC-w/o liquid diet) and one that was sacrifi ced at 21 days (VRC-w/o liquid diet). One bird in the 21-day VRC-liquid diet group had amyloid deposition in sinusoids, and one had it, rarely, within blood vessels. Changes in the kidneys were rare and insignifi cant (mild focal interstitial fi brosis and rare clusters of interstitial lymphocytes in one bird each, and two birds with luminal mineral concretions, rarely, in tubules).
Discussion
The results from this study show that a single dose of VRC administered to mallard ducks at 10 mg/kg IV or 10, 20, and 40 mg/kg PO was well tolerated and did not result in any observed clinical signs of toxicity. Similarly, a daily dose of VRC 20 mg/kg for 21 days did not result in any observed clinical signs of toxicity. In humans, reported adverse reactions include hepatotoxicity, visual disturbances, skin rash, and neurological, hematological and renal abnormalities [39, 40] . In cats, adverse neurological events have also been associated with voriconazole administration [41] . In our study, the birds continued to be alert, ambulated normally, did not appear to have any visual defi cits, consumed food and water normally and had normal fecal output (both amounts and consistency). This is similar to what has been reported for Amazon [28] , and African Grey [27] parrots, and falcons [42] in which clinically evident toxicity was not observed with similar shortterm repeated dosing. However, this was in contrast to one avian study, where the results imply that repeated doses of VRC might be problematic for pigeons [29] . In addition, one study reported adverse neurologic events when VRC was administered to cats [41] . In the pigeon study, one of 12 birds administered VRC at 10 mg/kg q12h for three days showed clinical signs (lying down) [29] . In that same study, 8 of 12 pigeons given a higher and more frequent dose of VRC (20 mg/kg q12 h for 4 days) demonstrated at least one of the following clinical signs; ruffl ed feathers, laying down, swollen crop and retching, and stretching the neck [29] . Although no clinical signs of toxicity were observed in the ducks from our study, the evaluation of aspartate aminotransferase and glutamate dehydrogenase activities and bile acids might have been informative to assess potential hepatotoxicity. From a histological perspective, oral administration of 20 mg/kg VRC q24 h, with and without liquid diet, did not result in microscopic changes indicative of drug toxicity in the livers and kidneys of ducks after 1, 7, 14 or 21 days of treatment. Unfortunately, due to study limitations, there was only one control bird. This single bird did not provide the statistical power necessary to demonstrate that the lesions seen in the negative control bird were the same as those seen in VRC-treated birds. Despite this limitation, no histologic lesions could be correlated with administration route (IV vs PO) or length of treatment. Portal infl ammation was seen in the liver sections from VRC-treated ducks and the untreated, negative control duck. However, this histologic fi nding is a nonspecifi c change and is not a typical response to toxic insult, but rather a response to intestinal antigens or residuum of prior liver infl ammation [43] . The most clinically signifi cant change seen in the liver was the amyloid deposition in the sinusoids in one bird. Amyloidosis in birds is caused by deposition of amyloid, a protein that is typically associated with underlying infectious or infl ammatory conditions. Waterfowl are most susceptible to amyloidosis [44] . Hepatic amyloidosis is sometimes seen in avian species associated with bacterial infections, and therefore this change is possibly a response to bacteria and was an individual fi nding. Vascular changes seen in tissue samples from two birds were focal and therefore not likely clinically signifi cant nor a response to the drug. In a related study, pigeons that received VRC at 10 mg/kg q12 h for 3 days ( n ϭ 12) or 20 mg/kg q24 h for 4 days ( n ϭ 12) had changes in the liver that the authors attributed to VRC treatment [29] . The pigeons in both dosing regimens had moderate oval cell proliferation, moderate to marked hepatocellular vacuolization, occasional random hepatocellular apoptosis, and moderate portal heterophilic and lymphocytic infi ltrates. In addition, pigeons that received a dose regimen of 20 mg/kg q12 h also had elevated biochemical parameters (uric acid, bile acids and/ or activities of aspartate aminotransferase or creatine kinase). In contrast to the pigeon study, oval cell proliferation was not seen in the ducks in the present study. From a pharmacokinetic standpoint, our study demonstrated that an oral VRC dosage of 20 mg/kg SID resulted in plasma concentrations that were above a targeted 0.5 μ g/ ml. This dosage is higher than the range of dosages (3 -10 mg/kg SID) reported for dogs, guinea pigs, rabbits and horses [23, 26] , but similar to what has been reported for rats and mice [23] and other species of birds [27, 45] , with the exception of the chicken [46] . For the ducks in our study, the supraproportional increases in C max and AUC 0 → ∞ with increasing doses of VRC indicated a lack of dose proportionality. In addition, inspection of the VRC plasma concentration data (e.g., plasma concentrations at 4 h postdosing) further supported a lack of dose proportionality. Given the similarity in terminal half-lives for the differing doses, the VRC plasma concentration data suggested the possibility for gastrointestinal fi rst pass effect. This lack of dose proportionality was not considered defi nitive for the ducks in our study given the limited subject sample size and the variability in the UPLC assay. Dose-dependent pharmacokinetics have been reported for VRC use in mammals and other birds [23, 27, 29, 46, 47] . Since biotransformation is the primary route of VRC elimination, a saturable process of metabolic clearance has been postulated to be the basis for this non-linearity.
The average oral VRC bioavailability for mallard ducks (61%) is similar to the 44% bioavailability found in pigeons comparing the same doses [29] . In humans, 90% bioavailability has been reported for VRC [47] and greater than 75% in other mammals with the exception of the alpaca [23, 26, 48] . Despite a relatively long wash out period (19 days), the bioavailability for the ducks in our study could have potentially been impacted by the residual effect of the fi rst study period given the cross over design. In addition, VRC may not be as well absorbed by the avian digestive tract or may undergo fi rst pass metabolism by intestinal P450 enzymes to a greater extent than in humans or many mammals. In addition, hepatic fi rst pass effect might have partially contributed to the reduced bioavailability since the mean plasma clearance (529 ml/kg • h) seemed low for Table 5 Noncompartmental pharmacokinetic parameters for mallard ducks ( n ϭ 6, separate populations) after oral daily dosing of VRC (20 mg/kg) with (VRC-liquid diet; 15 ml gavage fed) and without liquid diet (VRC-w/o liquid diet) for 21 days. Voriconazole plasma concentrations were measured using ultra performance liquid chromatography and corrected for recovery.
Parameter
Day [32] reported that administering VRC with food reduced the bioavailability of VRC when compared to fasting. However, the food source for the falcons and humans was more solid and substantial (meat or a regular meal), whereas the liquid diet given to the birds in our study was a highly digestible diet that was less likely to blunt drug absorption. The pharmacokinetics of VRC when administered to ducks over several days suggested potential autoinduction of cytochrome P450 metabolism. This phenomenon has been reported for other avian and mammalian species [23, 27, 47] . In the ducks, there was a statistically signifi cant change in pharmacokinetic parameters (AUC t , , C max , and T C Ͼ 0.5 ) over time after multiple days of VRC dosing. The lower AUC 0 → ∞ in 3 ducks given the oral dose after the IV dose in the bioavailability study may have also been the result of continued P450 induction, 19 days after a single dose. However, this fi nding should be interpreted with caution given the small sample size and the potential for individual variation. A reduction in AUC t has been noted in dogs [23] and to a greater extent in mice and rats [23] . In contrast, a 3-to 4-fold increase in the AUC t was reported for humans given VRC over 7 days [32] , and drug accumulation rather than autoinduction is also evident in the guinea pig and rabbit [32] . In mice, inhibition of P450s by grapefruit juice, given in lieu of regular drinking water, increases VRC concentrations with multiple dosing and improves the effi cacy of VRC against experimental fungal infections, but increasing clearance is still apparent [13, 51, 52] . In rats and dogs, increases in liver weight and P450 content have been associated with the decline in VRC exposure over multiple days dosing, an effect that was reversed in rats one month after cessation of VRC administration [23] . The isozyme of cytochrome P450 responsible for most VRC metabolism in humans is CYP2C19, while CYP2C9 and CYP3A4 also contribute [53] . The CYP2C and 3A subfamilies apparently also occur in birds, though specifi c forms differ substantially from those in mammals, and are inducible by other ergosterol biosynthesis-inhibiting antifungals [54 -56] .
Further support for autoinduction of VRC metabolism in the mallard ducks was the statistically signifi cant change in terminal elimination rates and half lives over time. African grey parrots in a multiple dose study were sampled at only one time, the trough after VRC administration at 18 mg/kg PO every 12 h, but plasma concentrations were signifi cantly lower on days 3 and 10 of dosing than 12 h after a single dose [27] . Declining VRC plasma concentrations at the expected trough times were also observed in domestic pigeons administered multiple doses, and estimated elimination half-lives decreased as well [29] . Comparing single IV doses, the elimination rates and clearance of VRC in ducks were approximately 10 times those found in pigeons, despite greater body size, so there is likely a species difference in VRC metabolism as well. VRC metabolism was not auto-induced in falcons, apparently, as putative peak and trough concentrations changed little on days 1 -7 and increased markedly after the day 14 dose [50] . The most clinically relevant pharmacokinetic change observed in the mallard ducks was the decrease in time that VRC concentrations were sustained over the target plasma concentration of 0.5 μ g/ml. The MIC 90 for Aspergillus fumigatus has been reported to be 0.5 μ g/ml for isolates from humans [10, 57] and various bird species [58] and the MIC 95 has been reported to be 0.38 μ g/ml for isolates from falcons [10, 57] . In humans treatment outcomes are improved when trough concentrations of VRC are Ͼ 1 μ g/ml [31] . In pigeons, administration of 20 mg/kg PO every 12 h maintained plasma concentrations above a targeted MIC of 0.38 ug/ml for 4 days but caused liver toxicity. VRC concentrations dropped below 0.38 ug/ml by 6 h after administration on the fourth day of 10 mg/kg PO q 12 h treatment when VRC elimination had increased [29] . Given the rapid elimination rate, mallard ducks given VRC once daily at 20 mg/kg will not maintain concentrations above 0.5 μ g/ml for 24 h. However, the safety of shorter dosing intervals or higher VRC dosages is unknown, therefore further studies are needed.
Published studies demonstrating relations between pharmacodynamic parameters (i.e., time the antibiotic serum concentration exceeds the MIC of the drug, the maximum serum concentration of the antibiotic achieved, and the area under the serum concentration-time curve in relation to MIC) and therapeutic outcomes for antifungal drugs are sparse compared to those for antibacterial antibiotics. For Candida albicans , a free drug AUC 0 → ∞ 24 /MIC ratio of 20:25 has been shown to predict effi cacy and has been suggested as a method for evaluating VRC treatment effi cacy [24, 59] . According to Toutain et al ., this ratio indicates that the average VRC plasma concentration for C. albicans should at least be equal to the MIC for the duration of the dosing interval [60] . In order to evaluate this relationship in mallard ducks, the extent of plasma protein binding of VRC would have to be investigated and MICs specifi c for Aspergillus spp. isolates from ducks obtained.
Although it has been documented that tissue concentrations are not necessarily indicative of what is happening at the site of infection in terms of active drug [61] , the tissue concentration data from our study provides basic information regarding VRC concentrations measured in organs at the time of sampling. These data are informative in understanding drug tissue penetration and retention. In addition, the information is useful if VRC is used in an extra label manner in mallard ducks intended for human food consumption. Given that a tolerance has not been established for this drug in any avian species, any detectable drug residues would be considered problematic from a food safety standpoint. Evaluation of VRC concentrations in the tissue samples from the ducks showed that very few of the samples had measurable concentrations when the samples were harvested 24 -36 h after the last dose was administered. Two other avian studies have investigated VRC tissue concentrations after multiple doses. In one pigeon study [29] , lung concentrations were evaluated in both 10 and 20 mg/kg treatment groups at both once and twice daily dosing intervals. For that study, 55 -75% of the lung tissue samples were below the LOQ (250 μ g/l) 10 -12 h after the fi nal dose. In another study, chickens were treated with 10 mg/kg VRC q24h and tissue samples were taken at 12 h post dosing on days 1, 10, 20, and 30 [46] . At 12 h post dosing, 50% of tissue samples had detectable drug levels with the highest levels detected in liver, skin, and kidney; however, individual tissue VRC levels from each bird varied considerably. The differences in tissue harvesting time relative to the last VRC dosing time (roughly 10 -12 h post drug treatment for chickens and pigeons versus 24 -36 h after dosing for ducks) could explain the differences between measurable VRC tissue concentrations in other bird studies and ours. The positive bias for the bioassay-determined VRC concentrations compared to the UPLC-determined VRC activities may have been due to the bioassay ' s detection of antifungal activity of unknown VRC metabolites present in duck plasma. The N -oxide metabolite that predominates in the human, rat, and dog has 1/100 the antifungal activity of VRC or less [23] , and acceptable agreement has been shown between a bioassay and UPLC assay of VRC in human clinical samples [31] . The major circulating metabolites of VRC in birds are unknown, however, and substantial diversity in the relative predominance of metabolic pathways exists between mammal species [23] .
In conclusion, this study demonstrated that VRC bioavailability after oral administration is relatively low in fasted mallard ducks. Although no liver function tests or liver enzyme activities were evaluated, oral administration of VRC at a dose of 20 mg/kg once daily for 21 days seemed relatively safe since no signs of toxicity were observed and there were no signifi cant histological fi ndings. However, the clinical effi cacy of VRC administered orally at a dose of 20 mg/kg once daily is unknown as plasma concentrations in mallard ducks were not sustained above the targeted MIC of 0.5 μ g/ml for the entire dosing interval and changes in pharmacokinetic parameters after long-term administration of the drug did suggest enzyme induction. The data from this study indicate that treatment of mallard ducks with VRC might require a dosing interval of at least every 8 -12 h at a dose of 20 mg/kg, however further studies are necessary.
